Search
Ranitidine
go.drugbank.com/drugs/DB00863ApprovedWithdrawnRanitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. … [A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.
RUS 3108
go.drugbank.com/drugs/DB05911ExperimentalRUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
Iodipamide
go.drugbank.com/drugs/DB04711ApprovedWithdrawnIodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_.
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigational[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022.
Levamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. … [L6232] Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis.
Histidine
go.drugbank.com/drugs/DB00117ApprovedInvestigationalNutraceuticalAn essential amino acid that is required for the production of histamine.
Paramethadione
go.drugbank.com/drugs/DB00617ApprovedIt is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalapproved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Propiolactone
go.drugbank.com/drugs/DB09348ApprovedWithdrawn[A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. Propiolactone was first commercially available in the United States in 1958.[A32144]